Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages

  Labianca, R ^a   Nordlinger, B ^b   Beretta, G D ^c   Mosconi, S ^a   Mandala M ^a   Cervantes, A ^d   Arnold, D ^e  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b HÔPITAL AMBROISE PARÉ   (France)

^c Humanitas Gavazzeni Hospital   (Italy)

^d UNIVERSITY OF VALENCIA   (Spain)

^e TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; COLON RESECTION; COLORECTAL ANASTOMOSIS; COLORECTAL CANCER; COLOSTOMY; DIARRHEA; ENDOSCOPIC POLYPECTOMY; FOLLOW UP; HUMAN; ILEORECTAL ANASTOMOSIS; NEUROTOXICITY; PERSONALIZED MEDICINE; POLYP; PRIORITY JOURNAL; RISK ASSESSMENT; SENSORY NEUROPATHY; WIDE EXCISION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 18; COLONIC NEOPLASMS; COLONOSCOPY; DEOXYCYTIDINE; EARLY DETECTION OF CANCER; EUROPE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OCCULT BLOOD; ORGANOPLATINUM COMPOUNDS; RISK; RISK ASSESSMENT; RISK FACTORS; SIGMOIDOSCOPY; TREATMENT OUTCOME;

EID: 84885341769     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt354     Document Type: Article

References (54)

1. GLOBOCAN 2008 website: globocan.iarc.fr. (12 July 2013, date last accessed).
2. Jemal A, Center M, deSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-1907.
3. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688-1694.
4. Bossetti C, Levi F, Rosato V et al. Recent trends in colorectal cancer mortality in Europe. Int J Cancer 2011; 129: 180-191.
5. Coleman MP, Quaresma M, Berrino F et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-756.
6. American Cancer Society Guidelines. Colorectal cancer early detection. http:// www.cancer.org.
7. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO consensus guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516.
8. Davis DM, Marcet JE, Frattini JC et al. Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg 2011; 213: 352-361.
9. Balmaña J, Balaguer F, Cervantes A, Arnold D. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2013; 24(Suppl. 6): vi72-79.
10. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Segnan N, Patnick J, von Karsa L (eds). 2010.
11. McDermott FT, Hughes ES, Pihl E et al. Prognosis in relation to symptom duration in colon cancer. Br J Surg 1981; 68: 846-849.
12. Ford AC, Veldhuyzen van Zanten SJO, Rodgers CC et al. Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut 2008; 57: 1545-1553.
13. Washington MK, Berlin J, Branton P et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 2009; 133: 1539-1551.
14. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol 2009; 16: 327-333.
15. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674-684.
16. Thirunavukarasu P, Sukumar S, Sathaiah M et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst 2011; 103: 689-697.
17. Edge SB, Byrd DR, Compton CC et al. (eds). AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer, 2010, pp. 143-164.
18. Busch OR, Hop WC, Hoynck van Pependrecht MA et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328: 1372-1376.
19. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite instability status as a predictor of benefit fromfluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
20. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for the lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226.
21. Sinicrope FA, Foster NR, Thibodeau SN et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863-875.
22. Tejpar S, Saridaki Z, Delorenzi M et al. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst 2011; 103: 841-844.
23. Roth AD, Delorenzi M, Tejpar S et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012; 104: 1635-1646.
24. McCleary NJ, Meyerhardt JA, Green E et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600-2606.
25. Tournigand C, André T, Bonnetain F et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012; 30: 3353-3360.
26. Weiser MR, Landmann RG, Kattan MW et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 2008; 26: 380-385.
27. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-2059.
28. Hewett PJ, Allardyce RA, Bagshaw PF et al. Short-term outcomes of the Australasian randomized clinical study comparing laparoscopic and conventional open surgical treatments for colon cancer: the ALCCaS trial. Ann Surg 2008; 248: 728-738.
29. Andrè T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
30. Andrè T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
31. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204.
32. Haller DG, Tabernero J, Maroun J et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471.
33. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
34. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25: 3456-3461.
35. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-3125.
36. Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16.
37. de Gramont A, Van Cutsem E, Schmoll HJ et al. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-1233.
38. Alberts SR, Sargent DJ, Nair S et al. Effect of oxaliplatin, fluorouracil and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383-1393.
39. Taieb J, Tabernero J, Mini E et al. Adjuvant FOLFOX-4 with or without cetuximab (CTX) in patients (PTS) with resected stage III colon cancer: DFS and OS results and subgroup analyses of the PETACC-8 Intergroup phase III trial. Ann Oncol 2012; 23(suppl 9): abstr # LBA4.
40. Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation and colorectal cancer survival. N Engl J Med 2012; 367: 1596-1606.
41. Bruinvels DJ, Stiggelbout AM, Kievit J et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219: 174-182.
42. Rosen M, Chan L, Beart RW, Jr et al. Follow-up of colorectal cancer: a metaanalysis. Dis Colon Rectum 1998; 41: 1116-1126.
43. Renehan AG, Egger M, Saunders MP et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and metaanalysis of randomised trials. BMJ 2002; 324: 813-819.
44. Tjandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 2007; 50: 1783-1799.
45. Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for nonmetastatic colorectal cancer. Cochrane Database Syst Rev 2007; CD002200.
46. Renehan AG, Egger M, Saunders MP et al. Mechanisms of improved survival from intensive follow-up in colorectal cancer. a hypothesis Br J Cancer 2005; 92: 430-433.
47. Chau I, Allen MJ, Cunningham D et al. The value of routine serum carcinoembryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22: 1420-1429.
48. Rex DK, Kahi CJ, Levin B et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130: 1865-1871.
49. Sargent DJ, Patiyil S, Yothers G et al. Endpoints for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol 2007; 29: 4569-4574.
50. Tsikitis VL, Malireddy K, Gree EA et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 2009; 27: 3671-3676.
51. Grunfeld E, Earle CC. The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr 2010; 25-30.
52. Sisler JJ, Taylor-Brown J, Nugent Z et al. Continuity of care of colorectal cancer survivors at the end of treatment: the oncology-primary care interface. J Cancer Surviv 2012; 6: 468-475.
53. Howell D, Hack TF, Oliver TK et al. Models of care for post-treatment follow-up of adult cancer survivors: a systematic review and quality appraisal of the evidence. J Cancer Surviv 2012; 6: 359-371.
54. Grunfeld E, Earle CC, Stovall E. A framework for cancer survivorship research and translation to policy. Cancer Epidemiol Biomarkers Prev 2011; 20: 2099-2104.